Key result
Metabolic modulating agents that shift myocardial substrate utilization from fatty acid to glucose oxidation offer a potential therapeutic paradigm for ischemic heart disease and heart failure.
Population
Patients with cardiovascular disease, specifically chronic stable angina and ischaemic or non-ischaemic…
Design
Review
Authors
Loading...
Metabolic modulation remains investigational for IHD and HF; leaves open clinical utility pending randomized trials.
Metabolic modulation to increase myocardial efficiency represents a promising therapeutic paradigm for chronic stable angina and heart failure.
Beadle et al. (2010) conducted a review in Cardiovascular disease. Metabolic modulating agents was evaluated. Metabolic modulating agents that shift myocardial substrate utilization from fatty acid to glucose oxidation offer a potential therapeutic paradigm for ischemic heart disease and heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: